Imago Raises $80m Series C To Take Bomedemstat Into Phase III
Company Plans IPO In 2021 To Fund Additional Pivotal Trials
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.
You may also be interested in...
Merck Plans To ‘Tuck In’ Imago And Its Phase III-Ready Hematologic Candidate
After not closing a deal this year on Seagen, Merck takes a smaller step with a $1.35bn bid for Imago and its candidate for multiple myeloproliferative neoplasm indications.
Finance Watch: The Bigger The Better? Erasca, Imago Rise After IPOs
Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings.
Inrebic Approval Is A Boost For Myelofibrosis And Celgene's Buyer Bristol
Investors in Impact Biosciences, which sold the selective JAK2 inhibitor to Celgene for $1.1bn up front, could double their money with milestone fees based on fedratinib's approval.